Compare BORR & PRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BORR | PRCT |
|---|---|---|
| Founded | 2016 | 2009 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Medical Specialities |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 995.8M | 1.2B |
| IPO Year | 2017 | 2021 |
| Metric | BORR | PRCT |
|---|---|---|
| Price | $3.44 | $24.55 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 7 | 15 |
| Target Price | $4.93 | ★ $22.75 |
| AVG Volume (30 Days) | ★ 8.5M | 1.1M |
| Earning Date | 11-18-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1.71 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $308,054,000.00 |
| Revenue This Year | N/A | $28.44 |
| Revenue Next Year | $17.14 | $20.02 |
| P/E Ratio | $20.64 | ★ N/A |
| Revenue Growth | N/A | ★ 37.22 |
| 52 Week Low | $2.89 | $16.67 |
| 52 Week High | $6.66 | $38.11 |
| Indicator | BORR | PRCT |
|---|---|---|
| Relative Strength Index (RSI) | 43.43 | 69.49 |
| Support Level | $3.10 | $20.22 |
| Resistance Level | $4.64 | $26.41 |
| Average True Range (ATR) | 0.20 | 1.52 |
| MACD | -0.00 | 0.33 |
| Stochastic Oscillator | 31.90 | 97.58 |
Borr Drilling Ltd is an offshore shallow-water drilling contractor providing services to the oil and gas industry. Its operations focus on the ownership, contracting, and operation of jack-up rigs in shallow-water areas, including the provision of related equipment and work crews to conduct oil and gas drilling and workover operations for exploration and production (E&P) customers. The company contracts its rigs on a dayrate basis to drill wells for integrated oil companies, state-owned national oil companies, and independent oil and gas companies. It operates in one reportable segment.
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.